Cross-site concordance evaluation of tumor DNA and RNA sequencing platforms for the CIMAC-CIDC network.

CONCLUSIONS: The CIMAC collaborating laboratory platforms effectively generated consistent WES and RNA-seq data and enable robust cross-trial comparisons and meta-analyses of highly complex immuno-oncology biomarker data across the NCI CIMAC-CIDC Network.
PMID: 33323402 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 15, 2020 Category: Cancer & Oncology Authors: Zeng Z, Fu J, Cibulskis C, Jhaveri A, Gumbs C, Das B, Sanchez-Espiridion B, Janssens S, Taing L, Wang J, Lindsay J, Vilimas T, Zhang J, Tokheim C, Das Sahu A, Jiang P, Yan C, Duose DY, Cerami E, Chen L, Cohen D, Chen QR, Enos RA, Huang X, Lee JJ, Liu Y, N Tags: Clin Cancer Res Source Type: research